Serum markers in patients with resectable pancreatic adenocarcinoma: Macrophage inhibitory cytokine 1 versus CA19-9

Clinical Cancer Research

Volumn 12, Issue 2, 2006, Pages 442-446

  Koopmann, Jens ^a   Rosenzweig, C Nicole White ^a   Zhang, Zhen ^a   Canto, Marcia I ^a   Brown, David A ^b   Hunter, Mark ^b   Yeo, Charles ^a   Chan, Daniel W ^a   Breit, Samuel N ^b   Goggins, Michael ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CYTOKINE; MACROPHAGE INHIBITORY CYTOKINE 1; OSTEOPONTIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CHRONIC PANCREATITIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PANCREAS RESECTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SERUM;

ADENOCARCINOMA; AGED; ANTIGENS, NEOPLASM; CA-19-9 ANTIGEN; CASE-CONTROL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LECTINS, C-TYPE; MALE; MIDDLE AGED; OSTEOPONTIN; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PROGNOSIS; SIALOGLYCOPROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 31544450588     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0564     Document Type: Article

References (47)

1. Association AG. American Gastroenterological Association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 1999;117:1463-84.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
3. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg 1995;221:721-31.
4. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999;131:247-55.
5. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high risk individuals. Clin Gastro Hepatol 2004;2:606-21.
6. Canto M, GM, Yeo C, et al. Screening for pancreatic neoplasia in asymptomatic high risk individuals: 3 prospective, controlled study. AACR/Lustgarten Foundation Pancreatic Cancer Research Meeting, San Francisco, June 25, 2004.
7. Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 2002;16:37-52.
8. Tumour markers in gastrointestinal cancers-EGTM recommendations. European Group on Tumour Markers. Anticancer Res 1999;19:2811-5.
9. Pleskow DK, Berher HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989;110:704-9.
10. DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999;117:1464-84.
11. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350-5.
12. Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol 1999;10 Suppl 4:145-9.
13. Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol 2005;23:4524-31.
14. Iacobuzio-Donanue CA, Ashfaq R, Maitra A, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003;63:8614-22.
15. Koopmann J, Buckhaults P, Brown DA, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 2004;10:2386-92.
16. Koopmann J, Fedarko NS, Jain A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004;13:487-91.
17. Zhou W, Sokoll LJ, Bruzek DJ, et al. TIMP-1 as a diagnostic marker for pancreatic cancer. Cancer Epidemiology Biomarkers Prev 1997;7:109-12.
18. Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002;62:1868-75.
19. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C. CEA, CA19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002;22:2311-6.
20. Chari ST, Klee GG, Miller LJ, Raimondo M, DiMagno EP. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology 2001;121:640-5.
21. Kawa S, Oguchi H, Kobayashi T, et al. Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. Br J Cancer 1991;64:899-902.
22. Yiannakou JY, Newland P, Calder F, Kingsnorth AN, Rhodes JM. Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer. Lancet 1997;349:389-92.
23. Slesak B, Harlozinska-Szmyrka A, Knast W, Sedlaczek P, van Dalen A, Einarsson R. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9. Cancer 2000;89:83-8.
24. Frena A. SPan-1 and exocrine pancreatic carcinoma. The clinical role of a new tumor marker. Int J Biol Markers 2001;16:189-97.
25. Palsson B, Masson P, Andren-Sandberg A. Tumour marker CA 50 levels compared to signs and symptoms in the diagnosis of pancreatic cancer. Eur J Surg Oncol 1997;23:151-6.
26. Hyoty M, Hyoty H, Aaran RK, Airo I, Nordback I. Tumour antigens CA195 and CA19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma. Eur J Surg 1992;158:173-9.
27. Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhava E. Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma. J Cancer Res Clin Oncol 1994;120:494-7.
28. Shahangian S, Fritsche HA, Jr., Hughes JI, Gelder FB. Pancreatic oncofetal antigen and carbohydrate antigen 19-9 in sera of patients with cancer of the pancreas. Clin Chem 1989;35:405-8.
29. Zhao XY, Yu SY, Da SP, et al. A clinical evaluation of serological diagnosis for pancreatic cancer. World J Gastroenterol 1998;4:147-9.
30. Schmiegel WH, Kreiker C, Eberl W, et al. Monoclonal antibody defines CA19-9 in pancreatic juices and sera. Gut 1985;26:456-60.
31. Fukushima N, Koopmann J, Sato N, et al. Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma. Mod Pathol 2005;18:779-87.
32. Schneider J, Schulze G. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res 2003;23:5089-93.
33. Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10:860-8.
34. Bhattacharyya S, Siegel ER, Petersen GM, Chari ST, Suva LJ, Haun RS. Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia 2004;6:674-86.
35. Swartz MJ, Batra SK, Varshney GC, et al. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol 2002;117:791-6.
36. Li Z, Sclabas GM, Peng B, et al. Overexpression of synuclein-γ in pancreatic adenocarcinoma. Cancer 2004;101:58-65.
37. Yokoyama-Kobayashi M, Saeki M, Sekine S, Kato S. Human cDNA encoding a novel TGF-β superfamily protein highly expressed in placenta. J Biochem (Tokyo) 1997;122:622-6.
38. Paralkar VM, Vail AL, Grasser WA, et al. Cloning and characterization of a novel member of the transforming growth factor-β/bone morphogenetic protein family. J Biol Chem 1998;273:13760-7.
39. Strelau J, Bottner M, Lingor P, et al. GDF-15/MIC-1a novel member of the TGF-β superfamily. J Neural Transm Suppl 2000;60:273-6.
40. Hromas R, Hufford M, Sutton J, Xu D, Li Y, Lu L. PLAB, a novel placental bone morphogenetic protein. Biochim Biophys Acta 1997;1354:40-4.
41. Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. Proc Natl Acad Sci U S A 1997;94:11514-9.
42. Buckhaults P, Rago C, St Croix B, et al. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res 2001;61:6996-7001.
43. Welsh JB, Sapinoso LM, Kern SG, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 2003;100:3410-5. Epub 2003 Mar 6.
44. Brown DA, Ward RL, Buckhaults P, et al. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003;9:2642-50.
45. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001;59:901-8.
46. Moore AG, Brown DA, Fairlie WD, et al. The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. J Clin Endocrinol Metab 2000;85:4781-8.
47. Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-8.